Boyouping (dulaglutide biosimilar)
/ Luye Group, Shandong Boan Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 27, 2023
Boan Biotech releases 2023 interim results: revenue grows steadily and profitability continues to increase [Google translation]
(Investing.com)
- "The Chinese phase III clinical trial of BA5101 (dulaglutide injection) in the field of metabolism has completed the enrollment of all subjects..."
Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 1
Of
1
Go to page
1